Clinical trial · Observational
Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia
Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia, Biomedical Research on Medical Devices Human ImmunTracker and Human Immun'IgH
NCT02520895CI-TRIAL-00018821RIPALcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RIPAL is a prospective cohort study, which main goal is to define T and B immune repertoire diversity and magnitude in patients with non-Hodgkin lymphoma of high and low grade and chronic lymphocytic leukemia before and after treatment, and to evaluate the association of these parameters with clinical patient data and outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| LYMPHOMA | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood samplings | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (8)
- label
- large B lymphoma cells (group 1)
- description
- 30 patients with large B lymphoma cells at diagnosis and who will receive an immunochemotherapy treatment patients will have blood samplings
- interventionNames
- Biological: blood samplings
- label
- indolent B-cell lymphomas (group 2)
- description
- 30 patients with indolent B-cell lymphomas without invasion excess blood lymphoma 1 giga / L at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
- interventionNames
- Biological: blood samplings
- label
- indolent B-cell lymphomas (group 3)
- description
- 20 Patients with indolent B-cell lymphomas with lymphocytosis (\> 1 Giga / L) at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 Years and older * Subjects with a diagnosis of large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, MALT, marginal zone, Waldenstrom's disease, chronic lymphocytic leukemia, T-cell lymphoma, anaplastic, cytotoxic or peripheral unspecified angioimmunoblastic. * Have signed an informed consent for participation in the study and preservation of blood samples for biomedical research. * Accept to appear in consultation biological samples at the sampling points corresponding to its group. * The benefits of social security. Exclusion Criteria: * Subjects with a diagnosis of Hodgkin disease * Subjects with a diagnosis of T-prolymphocytic leukemia * Subjects with a diagnosis of Burkitt's lymphoma * Subjects with a diagnosis of lymphoblastic lymphoma * Subjects who had prior-treatment for hematological disease * Patients under judicial safeguards
References
Publications (0)
Data not yet available
No reference posted for this study.